nodes	percent_of_prediction	percent_of_DWPC	metapath
Silodosin—CYP3A4—prostate cancer	0.169	1	CbGaD
Silodosin—UGT2B7—Epirubicin—prostate cancer	0.0684	0.142	CbGbCtD
Silodosin—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0464	0.0963	CbGbCtD
Silodosin—ABCB1—Estramustine—prostate cancer	0.0378	0.0785	CbGbCtD
Silodosin—ADRA1B—vas deferens—prostate cancer	0.0303	0.499	CbGeAlD
Silodosin—ABCB1—Cabazitaxel—prostate cancer	0.0249	0.0517	CbGbCtD
Silodosin—CYP3A4—Bicalutamide—prostate cancer	0.0244	0.0506	CbGbCtD
Silodosin—ABCB1—Estrone—prostate cancer	0.0244	0.0506	CbGbCtD
Silodosin—CYP3A4—Estramustine—prostate cancer	0.0227	0.047	CbGbCtD
Silodosin—ABCB1—Ethinyl Estradiol—prostate cancer	0.0217	0.0451	CbGbCtD
Silodosin—CYP3A4—Flutamide—prostate cancer	0.0202	0.0419	CbGbCtD
Silodosin—CYP3A4—Abiraterone—prostate cancer	0.0202	0.0419	CbGbCtD
Silodosin—ABCB1—Conjugated Estrogens—prostate cancer	0.0159	0.0331	CbGbCtD
Silodosin—CYP3A4—Cabazitaxel—prostate cancer	0.0149	0.031	CbGbCtD
Silodosin—CYP3A4—Estrone—prostate cancer	0.0146	0.0303	CbGbCtD
Silodosin—ABCB1—Mitoxantrone—prostate cancer	0.0145	0.0301	CbGbCtD
Silodosin—ABCB1—Estradiol—prostate cancer	0.014	0.029	CbGbCtD
Silodosin—CYP3A4—Ethinyl Estradiol—prostate cancer	0.013	0.027	CbGbCtD
Silodosin—ABCB1—Prednisone—prostate cancer	0.012	0.025	CbGbCtD
Silodosin—CYP3A4—Conjugated Estrogens—prostate cancer	0.00955	0.0198	CbGbCtD
Silodosin—ABCB1—Etoposide—prostate cancer	0.00914	0.019	CbGbCtD
Silodosin—CYP3A4—Mitoxantrone—prostate cancer	0.00868	0.018	CbGbCtD
Silodosin—CYP3A4—Estradiol—prostate cancer	0.00839	0.0174	CbGbCtD
Silodosin—ABCB1—Docetaxel—prostate cancer	0.00836	0.0174	CbGbCtD
Silodosin—CYP3A4—Prednisone—prostate cancer	0.00721	0.015	CbGbCtD
Silodosin—ABCB1—Doxorubicin—prostate cancer	0.00623	0.0129	CbGbCtD
Silodosin—CYP3A4—Etoposide—prostate cancer	0.00548	0.0114	CbGbCtD
Silodosin—CYP3A4—Docetaxel—prostate cancer	0.00501	0.0104	CbGbCtD
Silodosin—CYP3A4—Doxorubicin—prostate cancer	0.00373	0.00775	CbGbCtD
Silodosin—UGT2B7—prostate gland—prostate cancer	0.00334	0.055	CbGeAlD
Silodosin—ABCB4—testis—prostate cancer	0.00288	0.0473	CbGeAlD
Silodosin—ADRA1D—prostate gland—prostate cancer	0.00265	0.0436	CbGeAlD
Silodosin—CYP3A4—urine—prostate cancer	0.00254	0.0417	CbGeAlD
Silodosin—UGT2B7—renal system—prostate cancer	0.00228	0.0375	CbGeAlD
Silodosin—ABCB4—lymph node—prostate cancer	0.00209	0.0343	CbGeAlD
Silodosin—ADRA1D—epithelium—prostate cancer	0.00195	0.032	CbGeAlD
Silodosin—ADRA1B—renal system—prostate cancer	0.00185	0.0304	CbGeAlD
Silodosin—ADRA1D—urethra—prostate cancer	0.00177	0.0292	CbGeAlD
Silodosin—ADRA1A—prostate gland—prostate cancer	0.00152	0.025	CbGeAlD
Silodosin—UGT2B7—testis—prostate cancer	0.00147	0.0242	CbGeAlD
Silodosin—ADRA1A—epithelium—prostate cancer	0.00112	0.0184	CbGeAlD
Silodosin—ADRA1A—renal system—prostate cancer	0.00104	0.0171	CbGeAlD
Silodosin—ABCB1—prostate gland—prostate cancer	0.000645	0.0106	CbGeAlD
Silodosin—CYP3A4—renal system—prostate cancer	0.000621	0.0102	CbGeAlD
Silodosin—ABCB1—seminal vesicle—prostate cancer	0.000546	0.00897	CbGeAlD
Silodosin—ABCB1—epithelium—prostate cancer	0.000474	0.00779	CbGeAlD
Silodosin—ABCB1—renal system—prostate cancer	0.00044	0.00723	CbGeAlD
Silodosin—ABCB1—urethra—prostate cancer	0.000432	0.0071	CbGeAlD
Silodosin—ABCB1—bone marrow—prostate cancer	0.000332	0.00547	CbGeAlD
Silodosin—ABCB1—testis—prostate cancer	0.000284	0.00467	CbGeAlD
Silodosin—Insomnia—Goserelin—prostate cancer	0.000235	0.00147	CcSEcCtD
Silodosin—Headache—Bicalutamide—prostate cancer	0.000234	0.00146	CcSEcCtD
Silodosin—Nasopharyngitis—Capecitabine—prostate cancer	0.000233	0.00146	CcSEcCtD
Silodosin—Insomnia—Conjugated Estrogens—prostate cancer	0.000232	0.00145	CcSEcCtD
Silodosin—Asthenia—Ethinyl Estradiol—prostate cancer	0.000226	0.00141	CcSEcCtD
Silodosin—Syncope—Estradiol—prostate cancer	0.000226	0.00141	CcSEcCtD
Silodosin—Pruritus—Ethinyl Estradiol—prostate cancer	0.000223	0.00139	CcSEcCtD
Silodosin—Palpitations—Estradiol—prostate cancer	0.000223	0.00139	CcSEcCtD
Silodosin—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000222	0.00139	CcSEcCtD
Silodosin—Nausea—Bicalutamide—prostate cancer	0.000222	0.00139	CcSEcCtD
Silodosin—Loss of consciousness—Estradiol—prostate cancer	0.000222	0.00138	CcSEcCtD
Silodosin—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000216	0.00135	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.000213	0.00133	CcSEcCtD
Silodosin—Gastrointestinal pain—Goserelin—prostate cancer	0.000212	0.00133	CcSEcCtD
Silodosin—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.00021	0.00131	CcSEcCtD
Silodosin—Dry mouth—Estradiol—prostate cancer	0.00021	0.00131	CcSEcCtD
Silodosin—Dizziness—Ethinyl Estradiol—prostate cancer	0.000209	0.0013	CcSEcCtD
Silodosin—Cardiac disorder—Etoposide—prostate cancer	0.000208	0.0013	CcSEcCtD
Silodosin—Hepatic function abnormal—Epirubicin—prostate cancer	0.000208	0.0013	CcSEcCtD
Silodosin—Urticaria—Goserelin—prostate cancer	0.000206	0.00129	CcSEcCtD
Silodosin—ABCB1—lymph node—prostate cancer	0.000206	0.00339	CbGeAlD
Silodosin—Abdominal pain—Goserelin—prostate cancer	0.000205	0.00128	CcSEcCtD
Silodosin—Urticaria—Conjugated Estrogens—prostate cancer	0.000204	0.00128	CcSEcCtD
Silodosin—Angiopathy—Etoposide—prostate cancer	0.000204	0.00127	CcSEcCtD
Silodosin—Vascular purpura—Epirubicin—prostate cancer	0.000203	0.00127	CcSEcCtD
Silodosin—Abdominal pain—Conjugated Estrogens—prostate cancer	0.000203	0.00127	CcSEcCtD
Silodosin—Immune system disorder—Etoposide—prostate cancer	0.000203	0.00127	CcSEcCtD
Silodosin—Jaundice—Docetaxel—prostate cancer	0.000203	0.00127	CcSEcCtD
Silodosin—Shock—Estradiol—prostate cancer	0.000202	0.00127	CcSEcCtD
Silodosin—Mediastinal disorder—Etoposide—prostate cancer	0.000202	0.00126	CcSEcCtD
Silodosin—Nervous system disorder—Estradiol—prostate cancer	0.000202	0.00126	CcSEcCtD
Silodosin—Tachycardia—Estradiol—prostate cancer	0.000201	0.00126	CcSEcCtD
Silodosin—Skin disorder—Estradiol—prostate cancer	0.0002	0.00125	CcSEcCtD
Silodosin—Rash—Ethinyl Estradiol—prostate cancer	0.000199	0.00124	CcSEcCtD
Silodosin—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000199	0.00124	CcSEcCtD
Silodosin—Headache—Ethinyl Estradiol—prostate cancer	0.000198	0.00123	CcSEcCtD
Silodosin—Hepatobiliary disease—Docetaxel—prostate cancer	0.000196	0.00123	CcSEcCtD
Silodosin—Jaundice—Capecitabine—prostate cancer	0.000196	0.00123	CcSEcCtD
Silodosin—Hepatic function abnormal—Doxorubicin—prostate cancer	0.000193	0.0012	CcSEcCtD
Silodosin—Hepatobiliary disease—Capecitabine—prostate cancer	0.00019	0.00119	CcSEcCtD
Silodosin—Purpura—Epirubicin—prostate cancer	0.000189	0.00118	CcSEcCtD
Silodosin—Shock—Mitoxantrone—prostate cancer	0.000189	0.00118	CcSEcCtD
Silodosin—Vascular purpura—Doxorubicin—prostate cancer	0.000188	0.00118	CcSEcCtD
Silodosin—Nausea—Ethinyl Estradiol—prostate cancer	0.000187	0.00117	CcSEcCtD
Silodosin—Tachycardia—Mitoxantrone—prostate cancer	0.000187	0.00117	CcSEcCtD
Silodosin—Asthenia—Goserelin—prostate cancer	0.000186	0.00116	CcSEcCtD
Silodosin—Skin disorder—Mitoxantrone—prostate cancer	0.000186	0.00116	CcSEcCtD
Silodosin—Insomnia—Estradiol—prostate cancer	0.000186	0.00116	CcSEcCtD
Silodosin—Erectile dysfunction—Prednisone—prostate cancer	0.000185	0.00116	CcSEcCtD
Silodosin—Asthenia—Conjugated Estrogens—prostate cancer	0.000184	0.00115	CcSEcCtD
Silodosin—Pruritus—Goserelin—prostate cancer	0.000184	0.00115	CcSEcCtD
Silodosin—Pruritus—Conjugated Estrogens—prostate cancer	0.000182	0.00114	CcSEcCtD
Silodosin—Hypotension—Mitoxantrone—prostate cancer	0.000179	0.00112	CcSEcCtD
Silodosin—Gastrointestinal disorder—Estradiol—prostate cancer	0.000178	0.00111	CcSEcCtD
Silodosin—Diarrhoea—Goserelin—prostate cancer	0.000178	0.00111	CcSEcCtD
Silodosin—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000176	0.0011	CcSEcCtD
Silodosin—Purpura—Doxorubicin—prostate cancer	0.000175	0.00109	CcSEcCtD
Silodosin—Cardiac disorder—Docetaxel—prostate cancer	0.000173	0.00108	CcSEcCtD
Silodosin—Loss of consciousness—Etoposide—prostate cancer	0.000172	0.00107	CcSEcCtD
Silodosin—Dizziness—Goserelin—prostate cancer	0.000172	0.00107	CcSEcCtD
Silodosin—Dizziness—Conjugated Estrogens—prostate cancer	0.00017	0.00106	CcSEcCtD
Silodosin—Angiopathy—Docetaxel—prostate cancer	0.000169	0.00106	CcSEcCtD
Silodosin—Immune system disorder—Docetaxel—prostate cancer	0.000168	0.00105	CcSEcCtD
Silodosin—Gastrointestinal pain—Estradiol—prostate cancer	0.000168	0.00105	CcSEcCtD
Silodosin—Mediastinal disorder—Docetaxel—prostate cancer	0.000168	0.00105	CcSEcCtD
Silodosin—Liver function test abnormal—Epirubicin—prostate cancer	0.000168	0.00105	CcSEcCtD
Silodosin—Cardiac disorder—Capecitabine—prostate cancer	0.000168	0.00105	CcSEcCtD
Silodosin—Orthostatic hypotension—Epirubicin—prostate cancer	0.000166	0.00104	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000165	0.00103	CcSEcCtD
Silodosin—Breast disorder—Epirubicin—prostate cancer	0.000164	0.00103	CcSEcCtD
Silodosin—Angiopathy—Capecitabine—prostate cancer	0.000164	0.00102	CcSEcCtD
Silodosin—Rash—Goserelin—prostate cancer	0.000164	0.00102	CcSEcCtD
Silodosin—Dermatitis—Goserelin—prostate cancer	0.000163	0.00102	CcSEcCtD
Silodosin—Urticaria—Estradiol—prostate cancer	0.000163	0.00102	CcSEcCtD
Silodosin—Mental disorder—Docetaxel—prostate cancer	0.000163	0.00102	CcSEcCtD
Silodosin—Immune system disorder—Capecitabine—prostate cancer	0.000163	0.00102	CcSEcCtD
Silodosin—Mediastinal disorder—Capecitabine—prostate cancer	0.000163	0.00102	CcSEcCtD
Silodosin—Abdominal pain—Estradiol—prostate cancer	0.000163	0.00102	CcSEcCtD
Silodosin—Nasopharyngitis—Epirubicin—prostate cancer	0.000163	0.00102	CcSEcCtD
Silodosin—Headache—Goserelin—prostate cancer	0.000163	0.00102	CcSEcCtD
Silodosin—Rash—Conjugated Estrogens—prostate cancer	0.000162	0.00101	CcSEcCtD
Silodosin—Dermatitis—Conjugated Estrogens—prostate cancer	0.000162	0.00101	CcSEcCtD
Silodosin—Headache—Conjugated Estrogens—prostate cancer	0.000161	0.00101	CcSEcCtD
Silodosin—Mental disorder—Capecitabine—prostate cancer	0.000158	0.000989	CcSEcCtD
Silodosin—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000157	0.00098	CcSEcCtD
Silodosin—Tachycardia—Etoposide—prostate cancer	0.000156	0.000973	CcSEcCtD
Silodosin—Liver function test abnormal—Doxorubicin—prostate cancer	0.000155	0.000971	CcSEcCtD
Silodosin—Skin disorder—Etoposide—prostate cancer	0.000155	0.000968	CcSEcCtD
Silodosin—Nausea—Goserelin—prostate cancer	0.000154	0.000964	CcSEcCtD
Silodosin—Orthostatic hypotension—Doxorubicin—prostate cancer	0.000154	0.000961	CcSEcCtD
Silodosin—Nausea—Conjugated Estrogens—prostate cancer	0.000153	0.000954	CcSEcCtD
Silodosin—Urticaria—Mitoxantrone—prostate cancer	0.000152	0.000952	CcSEcCtD
Silodosin—Breast disorder—Doxorubicin—prostate cancer	0.000152	0.00095	CcSEcCtD
Silodosin—Abdominal pain—Mitoxantrone—prostate cancer	0.000152	0.000947	CcSEcCtD
Silodosin—Nasopharyngitis—Doxorubicin—prostate cancer	0.00015	0.000941	CcSEcCtD
Silodosin—Hypotension—Etoposide—prostate cancer	0.000149	0.000931	CcSEcCtD
Silodosin—Asthenia—Estradiol—prostate cancer	0.000148	0.000923	CcSEcCtD
Silodosin—Angiopathy—Prednisone—prostate cancer	0.000146	0.000912	CcSEcCtD
Silodosin—Syncope—Docetaxel—prostate cancer	0.000146	0.00091	CcSEcCtD
Silodosin—Pruritus—Estradiol—prostate cancer	0.000146	0.00091	CcSEcCtD
Silodosin—Immune system disorder—Prednisone—prostate cancer	0.000145	0.000908	CcSEcCtD
Silodosin—Palpitations—Docetaxel—prostate cancer	0.000143	0.000897	CcSEcCtD
Silodosin—Loss of consciousness—Docetaxel—prostate cancer	0.000143	0.000892	CcSEcCtD
Silodosin—Syncope—Capecitabine—prostate cancer	0.000141	0.000881	CcSEcCtD
Silodosin—Mental disorder—Prednisone—prostate cancer	0.000141	0.000881	CcSEcCtD
Silodosin—Diarrhoea—Estradiol—prostate cancer	0.000141	0.00088	CcSEcCtD
Silodosin—Palpitations—Capecitabine—prostate cancer	0.000139	0.000868	CcSEcCtD
Silodosin—Loss of consciousness—Capecitabine—prostate cancer	0.000138	0.000864	CcSEcCtD
Silodosin—Gastrointestinal disorder—Etoposide—prostate cancer	0.000138	0.00086	CcSEcCtD
Silodosin—Asthenia—Mitoxantrone—prostate cancer	0.000138	0.00086	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000137	0.000858	CcSEcCtD
Silodosin—Jaundice—Epirubicin—prostate cancer	0.000137	0.000854	CcSEcCtD
Silodosin—Dizziness—Estradiol—prostate cancer	0.000136	0.00085	CcSEcCtD
Silodosin—Dry mouth—Docetaxel—prostate cancer	0.000135	0.000845	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000133	0.000831	CcSEcCtD
Silodosin—Hepatobiliary disease—Epirubicin—prostate cancer	0.000133	0.000828	CcSEcCtD
Silodosin—Sinusitis—Epirubicin—prostate cancer	0.000131	0.000822	CcSEcCtD
Silodosin—Diarrhoea—Mitoxantrone—prostate cancer	0.000131	0.00082	CcSEcCtD
Silodosin—Dry mouth—Capecitabine—prostate cancer	0.000131	0.000818	CcSEcCtD
Silodosin—Gastrointestinal pain—Etoposide—prostate cancer	0.00013	0.000815	CcSEcCtD
Silodosin—Shock—Docetaxel—prostate cancer	0.00013	0.000815	CcSEcCtD
Silodosin—Nervous system disorder—Docetaxel—prostate cancer	0.00013	0.000812	CcSEcCtD
Silodosin—Rash—Estradiol—prostate cancer	0.00013	0.000811	CcSEcCtD
Silodosin—Dermatitis—Estradiol—prostate cancer	0.00013	0.00081	CcSEcCtD
Silodosin—Tachycardia—Docetaxel—prostate cancer	0.000129	0.000808	CcSEcCtD
Silodosin—Headache—Estradiol—prostate cancer	0.000129	0.000806	CcSEcCtD
Silodosin—Skin disorder—Docetaxel—prostate cancer	0.000129	0.000805	CcSEcCtD
Silodosin—Urticaria—Etoposide—prostate cancer	0.000127	0.000792	CcSEcCtD
Silodosin—Jaundice—Doxorubicin—prostate cancer	0.000126	0.00079	CcSEcCtD
Silodosin—Shock—Capecitabine—prostate cancer	0.000126	0.000789	CcSEcCtD
Silodosin—Abdominal pain—Etoposide—prostate cancer	0.000126	0.000788	CcSEcCtD
Silodosin—Nervous system disorder—Capecitabine—prostate cancer	0.000126	0.000786	CcSEcCtD
Silodosin—Syncope—Prednisone—prostate cancer	0.000126	0.000785	CcSEcCtD
Silodosin—Tachycardia—Capecitabine—prostate cancer	0.000125	0.000783	CcSEcCtD
Silodosin—Skin disorder—Capecitabine—prostate cancer	0.000125	0.000779	CcSEcCtD
Silodosin—Hypotension—Docetaxel—prostate cancer	0.000124	0.000774	CcSEcCtD
Silodosin—Loss of consciousness—Prednisone—prostate cancer	0.000123	0.000769	CcSEcCtD
Silodosin—Hepatobiliary disease—Doxorubicin—prostate cancer	0.000123	0.000767	CcSEcCtD
Silodosin—Nausea—Estradiol—prostate cancer	0.000122	0.000764	CcSEcCtD
Silodosin—Sinusitis—Doxorubicin—prostate cancer	0.000122	0.00076	CcSEcCtD
Silodosin—Rash—Mitoxantrone—prostate cancer	0.000121	0.000756	CcSEcCtD
Silodosin—Dermatitis—Mitoxantrone—prostate cancer	0.000121	0.000755	CcSEcCtD
Silodosin—Headache—Mitoxantrone—prostate cancer	0.00012	0.000751	CcSEcCtD
Silodosin—Hypotension—Capecitabine—prostate cancer	0.00012	0.000749	CcSEcCtD
Silodosin—Insomnia—Docetaxel—prostate cancer	0.00012	0.000749	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000118	0.00074	CcSEcCtD
Silodosin—Cardiac disorder—Epirubicin—prostate cancer	0.000117	0.00073	CcSEcCtD
Silodosin—Insomnia—Capecitabine—prostate cancer	0.000116	0.000725	CcSEcCtD
Silodosin—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000114	0.000715	CcSEcCtD
Silodosin—Asthenia—Etoposide—prostate cancer	0.000114	0.000715	CcSEcCtD
Silodosin—Angiopathy—Epirubicin—prostate cancer	0.000114	0.000713	CcSEcCtD
Silodosin—Nausea—Mitoxantrone—prostate cancer	0.000114	0.000712	CcSEcCtD
Silodosin—Immune system disorder—Epirubicin—prostate cancer	0.000114	0.00071	CcSEcCtD
Silodosin—Mediastinal disorder—Epirubicin—prostate cancer	0.000113	0.000709	CcSEcCtD
Silodosin—Pruritus—Etoposide—prostate cancer	0.000113	0.000705	CcSEcCtD
Silodosin—Shock—Prednisone—prostate cancer	0.000112	0.000703	CcSEcCtD
Silodosin—Nervous system disorder—Prednisone—prostate cancer	0.000112	0.000701	CcSEcCtD
Silodosin—Tachycardia—Prednisone—prostate cancer	0.000112	0.000697	CcSEcCtD
Silodosin—Skin disorder—Prednisone—prostate cancer	0.000111	0.000694	CcSEcCtD
Silodosin—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000111	0.000692	CcSEcCtD
Silodosin—Mental disorder—Epirubicin—prostate cancer	0.00011	0.000689	CcSEcCtD
Silodosin—Diarrhoea—Etoposide—prostate cancer	0.000109	0.000682	CcSEcCtD
Silodosin—Gastrointestinal pain—Docetaxel—prostate cancer	0.000108	0.000677	CcSEcCtD
Silodosin—Cardiac disorder—Doxorubicin—prostate cancer	0.000108	0.000675	CcSEcCtD
Silodosin—Angiopathy—Doxorubicin—prostate cancer	0.000106	0.00066	CcSEcCtD
Silodosin—Dizziness—Etoposide—prostate cancer	0.000105	0.000659	CcSEcCtD
Silodosin—Immune system disorder—Doxorubicin—prostate cancer	0.000105	0.000657	CcSEcCtD
Silodosin—Gastrointestinal pain—Capecitabine—prostate cancer	0.000105	0.000656	CcSEcCtD
Silodosin—Mediastinal disorder—Doxorubicin—prostate cancer	0.000105	0.000656	CcSEcCtD
Silodosin—Abdominal pain—Docetaxel—prostate cancer	0.000105	0.000655	CcSEcCtD
Silodosin—Insomnia—Prednisone—prostate cancer	0.000103	0.000646	CcSEcCtD
Silodosin—Mental disorder—Doxorubicin—prostate cancer	0.000102	0.000637	CcSEcCtD
Silodosin—Urticaria—Capecitabine—prostate cancer	0.000102	0.000637	CcSEcCtD
Silodosin—Abdominal pain—Capecitabine—prostate cancer	0.000101	0.000634	CcSEcCtD
Silodosin—Rash—Etoposide—prostate cancer	0.000101	0.000628	CcSEcCtD
Silodosin—Dermatitis—Etoposide—prostate cancer	0.0001	0.000628	CcSEcCtD
Silodosin—Headache—Etoposide—prostate cancer	9.99e-05	0.000624	CcSEcCtD
Silodosin—Syncope—Epirubicin—prostate cancer	9.82e-05	0.000614	CcSEcCtD
Silodosin—Palpitations—Epirubicin—prostate cancer	9.68e-05	0.000605	CcSEcCtD
Silodosin—Loss of consciousness—Epirubicin—prostate cancer	9.62e-05	0.000602	CcSEcCtD
Silodosin—Asthenia—Docetaxel—prostate cancer	9.51e-05	0.000594	CcSEcCtD
Silodosin—Nausea—Etoposide—prostate cancer	9.47e-05	0.000592	CcSEcCtD
Silodosin—Pruritus—Docetaxel—prostate cancer	9.37e-05	0.000586	CcSEcCtD
Silodosin—Gastrointestinal pain—Prednisone—prostate cancer	9.34e-05	0.000584	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	9.26e-05	0.000579	CcSEcCtD
Silodosin—Asthenia—Capecitabine—prostate cancer	9.2e-05	0.000575	CcSEcCtD
Silodosin—Dry mouth—Epirubicin—prostate cancer	9.12e-05	0.00057	CcSEcCtD
Silodosin—Syncope—Doxorubicin—prostate cancer	9.09e-05	0.000568	CcSEcCtD
Silodosin—Urticaria—Prednisone—prostate cancer	9.08e-05	0.000567	CcSEcCtD
Silodosin—Pruritus—Capecitabine—prostate cancer	9.08e-05	0.000567	CcSEcCtD
Silodosin—Diarrhoea—Docetaxel—prostate cancer	9.07e-05	0.000567	CcSEcCtD
Silodosin—Abdominal pain—Prednisone—prostate cancer	9.03e-05	0.000565	CcSEcCtD
Silodosin—Palpitations—Doxorubicin—prostate cancer	8.95e-05	0.00056	CcSEcCtD
Silodosin—Loss of consciousness—Doxorubicin—prostate cancer	8.91e-05	0.000557	CcSEcCtD
Silodosin—Shock—Epirubicin—prostate cancer	8.79e-05	0.00055	CcSEcCtD
Silodosin—Diarrhoea—Capecitabine—prostate cancer	8.78e-05	0.000549	CcSEcCtD
Silodosin—Nervous system disorder—Epirubicin—prostate cancer	8.76e-05	0.000548	CcSEcCtD
Silodosin—Dizziness—Docetaxel—prostate cancer	8.76e-05	0.000548	CcSEcCtD
Silodosin—Tachycardia—Epirubicin—prostate cancer	8.72e-05	0.000545	CcSEcCtD
Silodosin—Skin disorder—Epirubicin—prostate cancer	8.68e-05	0.000543	CcSEcCtD
Silodosin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	8.57e-05	0.000536	CcSEcCtD
Silodosin—Dizziness—Capecitabine—prostate cancer	8.48e-05	0.00053	CcSEcCtD
Silodosin—Dry mouth—Doxorubicin—prostate cancer	8.44e-05	0.000527	CcSEcCtD
Silodosin—Rash—Docetaxel—prostate cancer	8.35e-05	0.000522	CcSEcCtD
Silodosin—Hypotension—Epirubicin—prostate cancer	8.35e-05	0.000522	CcSEcCtD
Silodosin—Dermatitis—Docetaxel—prostate cancer	8.35e-05	0.000522	CcSEcCtD
Silodosin—Headache—Docetaxel—prostate cancer	8.3e-05	0.000519	CcSEcCtD
Silodosin—Asthenia—Prednisone—prostate cancer	8.2e-05	0.000513	CcSEcCtD
Silodosin—Shock—Doxorubicin—prostate cancer	8.14e-05	0.000509	CcSEcCtD
Silodosin—Nervous system disorder—Doxorubicin—prostate cancer	8.11e-05	0.000507	CcSEcCtD
Silodosin—Rash—Capecitabine—prostate cancer	8.09e-05	0.000506	CcSEcCtD
Silodosin—Pruritus—Prednisone—prostate cancer	8.08e-05	0.000505	CcSEcCtD
Silodosin—Insomnia—Epirubicin—prostate cancer	8.08e-05	0.000505	CcSEcCtD
Silodosin—Dermatitis—Capecitabine—prostate cancer	8.08e-05	0.000505	CcSEcCtD
Silodosin—Tachycardia—Doxorubicin—prostate cancer	8.07e-05	0.000505	CcSEcCtD
Silodosin—Headache—Capecitabine—prostate cancer	8.04e-05	0.000502	CcSEcCtD
Silodosin—Skin disorder—Doxorubicin—prostate cancer	8.03e-05	0.000502	CcSEcCtD
Silodosin—Nausea—Docetaxel—prostate cancer	7.87e-05	0.000492	CcSEcCtD
Silodosin—Diarrhoea—Prednisone—prostate cancer	7.82e-05	0.000489	CcSEcCtD
Silodosin—Hypotension—Doxorubicin—prostate cancer	7.73e-05	0.000483	CcSEcCtD
Silodosin—Gastrointestinal disorder—Epirubicin—prostate cancer	7.72e-05	0.000482	CcSEcCtD
Silodosin—Nausea—Capecitabine—prostate cancer	7.62e-05	0.000476	CcSEcCtD
Silodosin—Dizziness—Prednisone—prostate cancer	7.56e-05	0.000472	CcSEcCtD
Silodosin—Insomnia—Doxorubicin—prostate cancer	7.48e-05	0.000468	CcSEcCtD
Silodosin—Gastrointestinal pain—Epirubicin—prostate cancer	7.31e-05	0.000457	CcSEcCtD
Silodosin—Rash—Prednisone—prostate cancer	7.21e-05	0.00045	CcSEcCtD
Silodosin—Dermatitis—Prednisone—prostate cancer	7.2e-05	0.00045	CcSEcCtD
Silodosin—Headache—Prednisone—prostate cancer	7.16e-05	0.000448	CcSEcCtD
Silodosin—Gastrointestinal disorder—Doxorubicin—prostate cancer	7.14e-05	0.000446	CcSEcCtD
Silodosin—Urticaria—Epirubicin—prostate cancer	7.1e-05	0.000444	CcSEcCtD
Silodosin—Abdominal pain—Epirubicin—prostate cancer	7.07e-05	0.000442	CcSEcCtD
Silodosin—Nausea—Prednisone—prostate cancer	6.79e-05	0.000424	CcSEcCtD
Silodosin—Gastrointestinal pain—Doxorubicin—prostate cancer	6.76e-05	0.000423	CcSEcCtD
Silodosin—Urticaria—Doxorubicin—prostate cancer	6.57e-05	0.000411	CcSEcCtD
Silodosin—Abdominal pain—Doxorubicin—prostate cancer	6.54e-05	0.000409	CcSEcCtD
Silodosin—Asthenia—Epirubicin—prostate cancer	6.41e-05	0.000401	CcSEcCtD
Silodosin—Pruritus—Epirubicin—prostate cancer	6.32e-05	0.000395	CcSEcCtD
Silodosin—Diarrhoea—Epirubicin—prostate cancer	6.11e-05	0.000382	CcSEcCtD
Silodosin—Asthenia—Doxorubicin—prostate cancer	5.93e-05	0.000371	CcSEcCtD
Silodosin—Dizziness—Epirubicin—prostate cancer	5.91e-05	0.000369	CcSEcCtD
Silodosin—Pruritus—Doxorubicin—prostate cancer	5.85e-05	0.000366	CcSEcCtD
Silodosin—Diarrhoea—Doxorubicin—prostate cancer	5.66e-05	0.000354	CcSEcCtD
Silodosin—Rash—Epirubicin—prostate cancer	5.64e-05	0.000352	CcSEcCtD
Silodosin—Dermatitis—Epirubicin—prostate cancer	5.63e-05	0.000352	CcSEcCtD
Silodosin—Headache—Epirubicin—prostate cancer	5.6e-05	0.00035	CcSEcCtD
Silodosin—Dizziness—Doxorubicin—prostate cancer	5.47e-05	0.000342	CcSEcCtD
Silodosin—Nausea—Epirubicin—prostate cancer	5.31e-05	0.000332	CcSEcCtD
Silodosin—Rash—Doxorubicin—prostate cancer	5.21e-05	0.000326	CcSEcCtD
Silodosin—Dermatitis—Doxorubicin—prostate cancer	5.21e-05	0.000326	CcSEcCtD
Silodosin—Headache—Doxorubicin—prostate cancer	5.18e-05	0.000324	CcSEcCtD
Silodosin—Nausea—Doxorubicin—prostate cancer	4.91e-05	0.000307	CcSEcCtD
Silodosin—ABCB1—Metabolism—CYP2E1—prostate cancer	5.54e-06	4.3e-05	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—PTEN—prostate cancer	5.53e-06	4.3e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PIK3CG—prostate cancer	5.5e-06	4.27e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—APC—prostate cancer	5.5e-06	4.27e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTA2—prostate cancer	5.49e-06	4.26e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—NQO1—prostate cancer	5.48e-06	4.25e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—IL2—prostate cancer	5.44e-06	4.22e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—EGF—prostate cancer	5.44e-06	4.22e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—IRS1—prostate cancer	5.44e-06	4.22e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ABCG5—prostate cancer	5.42e-06	4.21e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—SULT1A1—prostate cancer	5.42e-06	4.21e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TERT—prostate cancer	5.42e-06	4.21e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—TH—prostate cancer	5.4e-06	4.19e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—LPL—prostate cancer	5.36e-06	4.16e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—CYP3A4—prostate cancer	5.34e-06	4.15e-05	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—IL2—prostate cancer	5.32e-06	4.13e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PDGFRB—prostate cancer	5.31e-06	4.13e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTA1—prostate cancer	5.29e-06	4.11e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—GSK3B—prostate cancer	5.28e-06	4.1e-05	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—EP300—prostate cancer	5.28e-06	4.1e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—PIK3CB—prostate cancer	5.26e-06	4.09e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—CYP1B1—prostate cancer	5.25e-06	4.08e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—NAT2—prostate cancer	5.23e-06	4.07e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—HSD3B2—prostate cancer	5.23e-06	4.07e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTO1—prostate cancer	5.23e-06	4.07e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—INS—prostate cancer	5.21e-06	4.04e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—HIF1A—prostate cancer	5.18e-06	4.02e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—ITGB3—prostate cancer	5.18e-06	4.02e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CREBBP—prostate cancer	5.1e-06	3.96e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—GGT1—prostate cancer	5.08e-06	3.95e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—LEP—prostate cancer	5.06e-06	3.93e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—CXCL8—prostate cancer	5.05e-06	3.93e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—IGF1—prostate cancer	5.04e-06	3.91e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—ERBB3—prostate cancer	5.02e-06	3.9e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—LRP2—prostate cancer	5.02e-06	3.9e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PLCB2—prostate cancer	5.02e-06	3.9e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CYP2C18—prostate cancer	5.02e-06	3.9e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—FGFR2—prostate cancer	5.01e-06	3.89e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CAV1—prostate cancer	5.01e-06	3.89e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—EGFR—prostate cancer	5.01e-06	3.89e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—NCOA1—prostate cancer	5.01e-06	3.89e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—KDR—prostate cancer	4.96e-06	3.85e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—CYP19A1—prostate cancer	4.94e-06	3.83e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—P4HB—prostate cancer	4.92e-06	3.82e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MAP2K1—prostate cancer	4.87e-06	3.78e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PIK3CD—prostate cancer	4.84e-06	3.76e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—IL2—prostate cancer	4.83e-06	3.75e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—ESR1—prostate cancer	4.83e-06	3.75e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TERT—prostate cancer	4.81e-06	3.74e-05	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—PIK3CA—prostate cancer	4.79e-06	3.72e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—SLC22A1—prostate cancer	4.79e-06	3.72e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—SERPINE1—prostate cancer	4.78e-06	3.71e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—RXRA—prostate cancer	4.76e-06	3.7e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—KRAS—prostate cancer	4.73e-06	3.68e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—BAD—prostate cancer	4.71e-06	3.66e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—SULT2A1—prostate cancer	4.67e-06	3.62e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—FGF2—prostate cancer	4.63e-06	3.6e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—HIF1A—prostate cancer	4.6e-06	3.58e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—MED12—prostate cancer	4.59e-06	3.57e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—COMT—prostate cancer	4.59e-06	3.56e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—GSTP1—prostate cancer	4.57e-06	3.55e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—NOS3—prostate cancer	4.57e-06	3.55e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PIK3CG—prostate cancer	4.57e-06	3.55e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—APC—prostate cancer	4.57e-06	3.55e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GNG5—prostate cancer	4.55e-06	3.54e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—IRS1—prostate cancer	4.51e-06	3.51e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—EGF—prostate cancer	4.51e-06	3.51e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—LEP—prostate cancer	4.49e-06	3.49e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—ITPR1—prostate cancer	4.49e-06	3.49e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CAV1—prostate cancer	4.45e-06	3.46e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—JAK2—prostate cancer	4.44e-06	3.45e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—KDR—prostate cancer	4.4e-06	3.42e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—NCOA3—prostate cancer	4.39e-06	3.41e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—GSK3B—prostate cancer	4.38e-06	3.4e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—PIK3CA—prostate cancer	4.35e-06	3.38e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MDM2—prostate cancer	4.33e-06	3.36e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—INS—prostate cancer	4.32e-06	3.36e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—ESR1—prostate cancer	4.29e-06	3.33e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—ERBB2—prostate cancer	4.27e-06	3.32e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—TYMS—prostate cancer	4.25e-06	3.3e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CREBBP—prostate cancer	4.23e-06	3.29e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PIK3CB—prostate cancer	4.21e-06	3.27e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—GSTM1—prostate cancer	4.2e-06	3.26e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—BAD—prostate cancer	4.19e-06	3.25e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—HPGDS—prostate cancer	4.18e-06	3.25e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—IGF1—prostate cancer	4.18e-06	3.25e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—EGFR—prostate cancer	4.16e-06	3.23e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CYP2C19—prostate cancer	4.16e-06	3.23e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—LPL—prostate cancer	4.12e-06	3.2e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ACHE—prostate cancer	4.06e-06	3.15e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTT1—prostate cancer	4.06e-06	3.15e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—APC—prostate cancer	4.06e-06	3.15e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PIK3CG—prostate cancer	4.06e-06	3.15e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CXCL8—prostate cancer	4.05e-06	3.15e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MAP2K1—prostate cancer	4.04e-06	3.14e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PIK3CD—prostate cancer	4.01e-06	3.12e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CYP2A6—prostate cancer	4.01e-06	3.12e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—IRS1—prostate cancer	4.01e-06	3.11e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—EGF—prostate cancer	4.01e-06	3.11e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—CYP1A1—prostate cancer	3.98e-06	3.09e-05	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—PIK3CA—prostate cancer	3.98e-06	3.09e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—SERPINE1—prostate cancer	3.97e-06	3.08e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CDKN1B—prostate cancer	3.96e-06	3.07e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—ERCC2—prostate cancer	3.95e-06	3.06e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—KRAS—prostate cancer	3.93e-06	3.05e-05	CbGpPWpGaD
Silodosin—ADRA1D—GPCR downstream signaling—AKT1—prostate cancer	3.91e-06	3.04e-05	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—PIK3CA—prostate cancer	3.9e-06	3.03e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—AKR1C3—prostate cancer	3.9e-06	3.03e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—GSK3B—prostate cancer	3.89e-06	3.02e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PRKACB—prostate cancer	3.88e-06	3.02e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CASP3—prostate cancer	3.88e-06	3.01e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—IL2—prostate cancer	3.87e-06	3.01e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—IL6—prostate cancer	3.85e-06	2.99e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—FGF2—prostate cancer	3.84e-06	2.98e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CYP17A1—prostate cancer	3.84e-06	2.98e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—INS—prostate cancer	3.84e-06	2.98e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—NOS3—prostate cancer	3.79e-06	2.94e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CCND1—prostate cancer	3.77e-06	2.93e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CREBBP—prostate cancer	3.76e-06	2.92e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CTNNB1—prostate cancer	3.74e-06	2.9e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—IGF1—prostate cancer	3.71e-06	2.88e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—MTHFR—prostate cancer	3.71e-06	2.88e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—EGFR—prostate cancer	3.69e-06	2.87e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—JAK2—prostate cancer	3.68e-06	2.86e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MMP9—prostate cancer	3.66e-06	2.85e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—NCOA2—prostate cancer	3.66e-06	2.84e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—CDKN1A—prostate cancer	3.65e-06	2.84e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PTEN—prostate cancer	3.64e-06	2.83e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PPARA—prostate cancer	3.64e-06	2.83e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—PIK3CA—prostate cancer	3.61e-06	2.8e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MDM2—prostate cancer	3.6e-06	2.79e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MAP2K1—prostate cancer	3.59e-06	2.79e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PIK3CD—prostate cancer	3.56e-06	2.77e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling by GPCR—AKT1—prostate cancer	3.55e-06	2.76e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—ERBB2—prostate cancer	3.54e-06	2.75e-05	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—PIK3CA—prostate cancer	3.53e-06	2.74e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—SERPINE1—prostate cancer	3.53e-06	2.74e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PIK3CB—prostate cancer	3.5e-06	2.72e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—SLC5A5—prostate cancer	3.49e-06	2.71e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—KRAS—prostate cancer	3.49e-06	2.71e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—EP300—prostate cancer	3.47e-06	2.7e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—CAV1—prostate cancer	3.42e-06	2.66e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—FGF2—prostate cancer	3.41e-06	2.65e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CYP2E1—prostate cancer	3.41e-06	2.65e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—SRC—prostate cancer	3.38e-06	2.62e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—NQO1—prostate cancer	3.37e-06	2.62e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—NOS3—prostate cancer	3.37e-06	2.61e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CXCL8—prostate cancer	3.36e-06	2.61e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—TH—prostate cancer	3.32e-06	2.58e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—VEGFA—prostate cancer	3.29e-06	2.56e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CDKN1B—prostate cancer	3.28e-06	2.55e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—JAK2—prostate cancer	3.27e-06	2.54e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—STAT3—prostate cancer	3.26e-06	2.53e-05	CbGpPWpGaD
Silodosin—ADRA1B—GPCR downstream signaling—AKT1—prostate cancer	3.25e-06	2.52e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CYP1B1—prostate cancer	3.23e-06	2.51e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CASP3—prostate cancer	3.22e-06	2.5e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—IL2—prostate cancer	3.21e-06	2.5e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	3.21e-06	2.49e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—IL6—prostate cancer	3.2e-06	2.48e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MDM2—prostate cancer	3.19e-06	2.48e-05	CbGpPWpGaD
Silodosin—UGT2B7—Metabolism—AKT1—prostate cancer	3.19e-06	2.48e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	3.15e-06	2.45e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GGT1—prostate cancer	3.13e-06	2.43e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CCND1—prostate cancer	3.13e-06	2.43e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PIK3CG—prostate cancer	3.12e-06	2.42e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	3.11e-06	2.41e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	3.1e-06	2.41e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—NCOA1—prostate cancer	3.09e-06	2.4e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MMP9—prostate cancer	3.04e-06	2.36e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CYP19A1—prostate cancer	3.04e-06	2.36e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	3.03e-06	2.35e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—MYC—prostate cancer	3.03e-06	2.35e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PTEN—prostate cancer	3.02e-06	2.35e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—TGFB1—prostate cancer	3.02e-06	2.35e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	2.99e-06	2.32e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—EGFR—prostate cancer	2.96e-06	2.3e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—INS—prostate cancer	2.95e-06	2.29e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	2.95e-06	2.29e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—RXRA—prostate cancer	2.93e-06	2.28e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	2.92e-06	2.26e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—CREBBP—prostate cancer	2.89e-06	2.24e-05	CbGpPWpGaD
Silodosin—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	2.88e-06	2.24e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—EP300—prostate cancer	2.88e-06	2.24e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CASP3—prostate cancer	2.86e-06	2.22e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—IL2—prostate cancer	2.85e-06	2.22e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—IL6—prostate cancer	2.84e-06	2.21e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—COMT—prostate cancer	2.83e-06	2.2e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTP1—prostate cancer	2.81e-06	2.19e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—SRC—prostate cancer	2.8e-06	2.18e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—KRAS—prostate cancer	2.8e-06	2.17e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CCND1—prostate cancer	2.78e-06	2.16e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ITPR1—prostate cancer	2.77e-06	2.15e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	2.75e-06	2.14e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PIK3CD—prostate cancer	2.74e-06	2.13e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	2.73e-06	2.12e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—STAT3—prostate cancer	2.7e-06	2.1e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MMP9—prostate cancer	2.7e-06	2.1e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	2.69e-06	2.09e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PTEN—prostate cancer	2.69e-06	2.09e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	2.62e-06	2.03e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—TYMS—prostate cancer	2.62e-06	2.03e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—NOS3—prostate cancer	2.59e-06	2.01e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—GSTM1—prostate cancer	2.59e-06	2.01e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—PIK3CA—prostate cancer	2.57e-06	2e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—EP300—prostate cancer	2.56e-06	1.99e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—LPL—prostate cancer	2.54e-06	1.97e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—MYC—prostate cancer	2.51e-06	1.95e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	2.51e-06	1.95e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—SRC—prostate cancer	2.49e-06	1.93e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—TP53—prostate cancer	2.49e-06	1.93e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—EGFR—prostate cancer	2.46e-06	1.91e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.45e-06	1.9e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—ERCC2—prostate cancer	2.43e-06	1.89e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	2.43e-06	1.88e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—STAT3—prostate cancer	2.4e-06	1.87e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PIK3CB—prostate cancer	2.39e-06	1.85e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PTGS2—prostate cancer	2.37e-06	1.84e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—KRAS—prostate cancer	2.32e-06	1.8e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—MTHFR—prostate cancer	2.28e-06	1.77e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—IL6—prostate cancer	2.28e-06	1.77e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PPARA—prostate cancer	2.24e-06	1.74e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—MYC—prostate cancer	2.23e-06	1.73e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	2.23e-06	1.73e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—EGFR—prostate cancer	2.18e-06	1.7e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	2.13e-06	1.66e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CAV1—prostate cancer	2.11e-06	1.64e-05	CbGpPWpGaD
Silodosin—ADRA1D—Signaling Pathways—AKT1—prostate cancer	2.1e-06	1.63e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PTEN—prostate cancer	2.06e-06	1.6e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—TP53—prostate cancer	2.06e-06	1.6e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—KRAS—prostate cancer	2.06e-06	1.6e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—EP300—prostate cancer	1.97e-06	1.53e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.92e-06	1.49e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	1.89e-06	1.47e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—IL6—prostate cancer	1.89e-06	1.47e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—TP53—prostate cancer	1.83e-06	1.42e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—INS—prostate cancer	1.82e-06	1.41e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—CREBBP—prostate cancer	1.78e-06	1.38e-05	CbGpPWpGaD
Silodosin—ADRA1B—Signaling Pathways—AKT1—prostate cancer	1.74e-06	1.35e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.69e-06	1.31e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—IL6—prostate cancer	1.68e-06	1.3e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—NOS3—prostate cancer	1.59e-06	1.24e-05	CbGpPWpGaD
Silodosin—ADRA1A—Signaling Pathways—AKT1—prostate cancer	1.55e-06	1.2e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.47e-06	1.14e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PTGS2—prostate cancer	1.46e-06	1.13e-05	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—PIK3CA—prostate cancer	1.46e-06	1.13e-05	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PTEN—prostate cancer	1.27e-06	9.87e-06	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—EP300—prostate cancer	1.21e-06	9.42e-06	CbGpPWpGaD
Silodosin—ABCB1—Metabolism—AKT1—prostate cancer	1.19e-06	9.23e-06	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—PIK3CA—prostate cancer	8.97e-07	6.96e-06	CbGpPWpGaD
Silodosin—CYP3A4—Metabolism—AKT1—prostate cancer	7.33e-07	5.69e-06	CbGpPWpGaD
